QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis

被引：0

作者：

Kotaka, M. ^{[1
]}

Bando, H. ^{[2
]}

Satake, H. ^{[3
]}

Kotani, D. ^{[4
]}

Hamaguchi, T. ^{[5
]}

Shiozawa, M. ^{[6
]}

Ikumoto, T. ^{[1
]}

Masuishi, T. ^{[7
]}

Yasui, H. ^{[8
]}

Kagawa, Y. ^{[9
]}

Oki, E. ^{[10
]}

Yamamoto, Y. ^{[11
]}

Kawakami, H. ^{[12
]}

Boku, S. ^{[13
]}

Komatsu, Y. ^{[14
]}

Taniguchi, H. ^{[7
]}

Muro, K. ^{[15
]}

Yamazaki, K. ^{[16
]}

Misumi, T. ^{[17
]}

Yoshino, T. ^{[4
]}

Kato, T. ^{[18
]}

Tsuji, A. ^{[16
]}

机构：

[1] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Japan

[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[3] Kochi Med Sch, Dept Med Oncol, Nankoku, Japan

[4] Natl Canc Ctr Hosp East, Kashiwa, Japan

[5] Saitama Med Univ, Int Med Ctr, Hidaka, Japan

[6] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan

[8] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Japan

[9] Osaka Gen Med Ctr, Dept Gastroenterol Surg, Osaka, Japan

[10] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan

[11] Univ Tsukuba, Dept Gastroenterol, Fac Med, Tsukuba, Japan

[12] Kindai Univ, Fac Med, Osakasayama, Japan

[13] Kansai Med Univ, Hirakata, Japan

[14] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan

[15] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan

[16] Shizuoka Canc Ctr, Dept Gastrointestinal Oncol, Shizuoka, Japan

[17] Natl Canc Ctr Hosp East, Dept Data Sci, Kashiwa, Japan

[18] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-149

引用

页码：S68 / S68

页数：1

共 50 条

[31] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
Gaspar, E.
Juarez Marroqui, A.
Vicent, J.
Llorca, C.
Orts, D.
Galan, A.
Barrajon, E.
Cervera Grau, J.
Giner, V.
Macia, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[32] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
Bai, Long
Wang, Feng
Li, Zhe-zhen
Ren, Chao
Zhang, Dong-sheng
Zhao, Qi
Lu, Yun-xin
Wang, De-shen
Ju, Huai-qiang
Qiu, Miao-zhen
Wang, Zhi-qiang
Wang, Feng-hua
Xu, Rui-hua
MEDICINE, 2016, 95 (51) : e4531
[33] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
Salvatore, L.
Loupakis, F.
Fontanini, G.
Cremolini, C.
Stasi, I.
Fabbri, A.
Ciarlo, A.
Granetto, C.
Basolo, F.
Falcone, A.
EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
[34] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
Salvatore, L.
Loupakis, F.
Cremolini, C.
Lupi, C.
Masi, G.
Sensi, E.
Stasi, I
Fornaro, L.
Vasile, E.
Schirripa, M.
Truscelli, K.
Giannini, R.
Baldi, G. G.
Altavilla, A.
Ciarlo, A.
Granetto, C.
Fea, E.
Fontanini, G.
Basolo, F.
Falcone, A.
ANNALS OF ONCOLOGY, 2009, 20
[35] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
Huang, Ching-Wen
Yeh, Yung-Sung
Ma, Cheng-Jen
Tsai, Hsiang-Lin
Chen, Chao-Wen
Huang, Ming-Yii
Lu, Chien-Yu
Wu, Jeng-Yih
Wang, Jaw Yuan
CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
[36] Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
Oki, Eiji
Makiyama, Akitaka
Miyamoto, Yuji
Kotaka, Masahiko
Kawanaka, Hirofumi
Miwa, Keisuke
Kabashima, Akira
Noguchi, Tomohiro
Yuge, Kotaro
Kashiwada, Tomomi
Ando, Koji
Shimokawa, Mototsugu
Saeki, Hiroshi
Akagi, Yoshito
Baba, Hideo
Maehara, Yoshihiko
Mori, Masaki
CANCER MEDICINE, 2021, 10 (02): : 454 - 461
[37] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
Miwa, Keisuke
Oki, Eiji
Emi, Yasunori
Saeki, Hiroshi
Kusumoto, Tetsuya
Akagi, Yoshito
Ogata, Yutaka
Samura, Hironori
Tokunaga, Shoji
Ishikawa, Hiroshi
Tanaka, Takaho
Sueyoshi, Susumu
Higashi, Hidefumi
Matsuda, Hiroyuki
Touyama, Tetsuo
Maehara, Yoshihiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 110 - 117
[38] FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
Cervantes, A.
Prager, G. W.
ESMO OPEN, 2023, 8 (02)
[39] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
Keisuke Miwa
Eiji Oki
Yasunori Emi
Hiroshi Saeki
Tetsuya Kusumoto
Yoshito Akagi
Yutaka Ogata
Hironori Samura
Shoji Tokunaga
Hiroshi Ishikawa
Takaho Tanaka
Susumu Sueyoshi
Hidefumi Higashi
Hiroyuki Matsuda
Tetsuo Touyama
Yoshihiko Maehara
International Journal of Clinical Oncology, 2016, 21 : 110 - 117
[40] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
Pinto, Ana Catarina
Teixeira, Margarida
Bonito, Nuno
Jacinto, Paula
Ribeiro, Joao
Gervasio, Helena
ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98

← 1 2 3 4 5 →